Synopsis
Synopsis
0
JDMF
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Boltin
2. Livial
3. Liviella
4. Org Od 14
5. Org Od14
6. Tibilone
1. 5630-53-5
2. Liviella
3. Livial
4. Org Od 14
5. Tibolona
6. Tibolonum
7. Xyvion
8. Boltin
9. (7r,8r,9s,13s,14s,17r)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
10. 17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one
11. Org-od 14
12. Chebi:32223
13. Ff9x0205v2
14. Nsc-759898
15. (1s,9r,10r,11s,14r,15s)-14-ethynyl-14-hydroxy-9,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-2(7)-en-5-one
16. Dsstox_cid_3667
17. (7alpha,17alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
18. Dsstox_rid_77135
19. Dsstox_gsid_23667
20. 17alpha-ethynyl-17beta-hydroxy-7alpha-methylestr-5(10)-en-3-one
21. (17r)-17-hydroxy-7alpha-methyl-19-norpregn-5(10)-en-20-yn-3-one
22. (7alpha,17beta)-17-ethynyl-17-hydroxy-7-methylestr-5(10)en-3-one
23. Cas-5630-53-5
24. Tibolonum [inn-latin]
25. Tibolona [inn-spanish]
26. Tibolone [usan:inn:ban]
27. Tibofem
28. Unii-ff9x0205v2
29. 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7.alpha.,17.alpha.)-
30. Ncgc00164632-01
31. Einecs 227-069-1
32. Tibolone [usan]
33. Org-od14
34. Tibolone [inn]
35. Tibolone [jan]
36. Tibolone [mi]
37. Tibolone [vandf]
38. Tibolone [mart.]
39. Tibolone [who-dd]
40. Schembl41172
41. Org Od 14;org Od14
42. Tibolone (jan/usan/inn)
43. Mls001424234
44. Tibolone [ep Impurity]
45. Gtpl9711
46. Tibolone [ep Monograph]
47. Chembl2103774
48. Dtxsid5023667
49. 17-hydroxy-7.alpha.-methyl-19-nor-17.alpha.-pregn-5(10)-en-20-yn-3-one
50. Hms2052k21
51. Hms2090b10
52. Hms2232b13
53. Hms3649j14
54. Hms3712j15
55. Zinc3812889
56. Tox21_112250
57. Kb-889
58. Akos015963197
59. Tox21_112250_1
60. Ccg-101148
61. Db09070
62. Gs-3562
63. Nc00398
64. Nsc 759898
65. Ncgc00164632-02
66. (7beta,8xi,9beta,13alpha,14beta,17alpha)-17-ethynyl-17-hydroxy-7-methylestr-5(10)-en-3-one
67. Ac-20036
68. Ac-31722
69. Cpd000469219
70. Smr000469219
71. D01639
72. T-3854
73. Ab00698273-05
74. 630t535
75. Q413805
76. Sr-01000763531
77. Sr-01000946727
78. Sr-01000763531-3
79. Sr-01000946727-1
80. 17.alpha.-hydroxy-7.alpha.-methyl-19-norpregn-5(10)-en-20-yn-3-one
81. 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-
Molecular Weight | 312.4 g/mol |
---|---|
Molecular Formula | C21H28O2 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 1 |
Exact Mass | 312.208930132 g/mol |
Monoisotopic Mass | 312.208930132 g/mol |
Topological Polar Surface Area | 37.3 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 636 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the relief of post-menopausal symptoms and for the prevention of osteoporosis.
Tibolone prevents bone loss and treating post-menopausal symptoms without stimulating the endometrial tissues, which may lead to malignancy. Typical, drugs that treat post-menopausal symptoms such as estrogen, have a proliferative effect on the endometrium, increasing the risk of endometrial carcinoma. The effects on the bone, brain and vaginal tissues can be explained by the estrogenic activity of tibolone. It is important to note that activity is not expressed in the endometrium. Tibolone behaves differently from estrogen plus progesterone combinations on the breast. Therefore, tibolone can be characterized as a selective estrogen activity regulator. Tibolone has been demonstrated to be an effective agent in treating symptoms associated with menopause. A 16 week trial in 1189 women examined the effect of tibolone 2.5 mg once daily on climacteric symptoms. Women treated with tibolone showed improvement from baseline in typical menopausal symptoms including hot flashes, sweating, insomnia, and anxiety.
Anabolic Agents
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)
Androgen Antagonists
Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Estrogen Receptor Modulators
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure. (See all compounds classified as Estrogen Receptor Modulators.)
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
G03CX01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03C - Estrogens
G03CX - Other estrogens
G03CX01 - Tibolone
Absorption
Tibolone is extensively and rapidly absorbed after oral administration. The parent drug undergoes extensive metabolism, with. Greater than 80% of a radioactive dose excreted from the body as metabolites, which suggests very low plasma concentrations of tibolone. Plasma concentrations of the metabolites appear within 30 minutes and peak within 11.5 hours.2,7 The plasma concentrations of the hydroxymetabolites are higher than those of the 4-isomer. Food does not appear to have an effect on the absorption of this drug.
Route of Elimination
Excreted in the urine and feces in the form of sulfated metabolites,. The predominant route of elimination of tibolone is via the feces, although some excretion occurs via the urine.
Clearance
Elimination of tibolone is not dependent renal function.
Tibolone is metabolized mainly in the liver. The cytochrome P450 isoenzyme system is involved in minor hydroxylation of tibolone. Tibolone is rapidly converted into three major metabolites: 3 alpha- and 3 beta-hydroxy-tibolone, which have oestrogenic effects, and the Delta(4)-isomer, which has both progestogenic and androgenic effects. The 3-hydroxy metabolites are present in the circulation, predominantly in their inactive sulfated form.
The elimination half-life is approximately 45 h.
This drug's effects are owed to the activity of its metabolites in various tissues. Upon ingestion, tibolone is quickly converted into three major metabolites: _3 alpha- and 3 beta-hydroxy-tibolone_, which have oestrogenic effects, and the _Delta(4)-isomer_, which has progestogenic and androgenic effects. The specific tissue-selective effects of tibolone occur due to the metabolism, regulation of enzymes and receptor activation that varies in different tissues of the body. The bone-conserving effects occur due to estradiol receptor activation, while the progesterone and androgen receptors are not involved in this process. Breast tissue of monkeys is not found to be stimulated after tibolone administration, as occurs with estrogen plus progesterone used in combination. This is explained by the fact that tibolone and its metabolites inhibit _sulphatase and 17 beta-hydroxysteroid dehydrogenase_ (HSD) type I and _stimulate sulphotransferase and 17 beta-HSD type II_. The combined effects of this process prevent the conversion to active estrogens. In the uterus, the progestogenic activity of the _Delta(4)-metabolite_ and the effect on estrogen-inactivating enzymes prevent estrogenic stimulation. The mammary gland is not stimulated in currently used animal models. Tibolone has been shown to regulate estrogenic activity in several tissue types by influencing the availability of estrogenic compounds for the estradiol receptor in a selective manner. Additionally, tibolone modulates cellular homeostasis in the breast by preventing breast tissue proliferation and stimulating cell apoptosis. Tibolone does not stimulate the endometrium because of the action of its highly stable progestogenic metabolite (Delta(4)-isomer) in combination with an effect on the sulfatase (inhibition)-sulfotransferase (stimulation) system. The estrogenic metabolites of tibolone have direct, favorable effects on the cardiovascular system and, in animal models, this drug has shown no adverse consequences. The tissue-selective effects of tibolone are the result of metabolism, enzyme regulation and receptor activation that vary in different tissues. The bone-preserving effects of tibolone are the result of estradiol receptor activation, while other steroid receptors, mainly the progesterone and androgen receptors, are not involved in this process. In a study of monkeys, breast tissue was not stimulated, which occurs with estrogen and progesterone, because tibolone and its metabolites inhibit _sulfatase and 17 beta-hydroxysteroid _dehydrogenase (HSD) type I and stimulate _sulfotransferase and 17 beta-HSD type II_. The simultaneous effects of this process halt conversion to active estrogens. Additionally, tibolone affects cellular homeostasis in the breast by preventing proliferation and stimulating apoptosis. Tibolone does not stimulate the endometrium due to the action of the highly stable progestogenic metabolite (Delta(4)-isomer) in combination with an effect on the sulphatase (inhibition)-sulphotransferase (stimulation) pathway. The levels of tibolone metabolites and the alteration of hormonal activities vary according to the tissue type. In endometrial tissue the _4-isomer_ functions as a progestagen, however, in the brain and liver, it shows androgenic effects. In breast tissue, the primary actions of tibolone are strong inhibition of sulfatase activity and weak inhibition of 17-hydroxysteroid dehydrogenase activity, which leads to blocking the conversion estrone sulfate to E2.
Certificate Number : R1-CEP 2012-173 - Rev 03
Issue Date : 2022-11-25
Type : Chemical
Substance Number : 1739
Status : Valid
Registrant Name : Synex Co., Ltd.
Registration Date : 2010-08-31
Registration Number : 20100831-140-H-28-01
Manufacturer Name : Aspen Oss BV
Manufacturer Address : Veersemeer 4, Oss, 5347 JN, The Netherlands
Available Reg Filing : ASMF, BR, CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29217
Submission : 2015-03-26
Status : Active
Type : II
Certificate Number : R1-CEP 2015-015 - Rev 00
Issue Date : 2021-02-11
Type : Chemical
Substance Number : 1739
Status : Valid
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2014-03-07
Registration Number : 20140306-140-H-248-03
Manufacturer Name : Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
Manufacturer Address : No.10, Longhai Road, Economic & Technological Development Zone, Qinhuangdao, Hebei, PRChina
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13895
Submission : 1998-12-14
Status : Inactive
Type : II
Date of Issue : 2020-09-08
Valid Till : 2023-04-24
Written Confirmation Number : WC-0402A2
Address of the Firm :
Certificate Number : R1-CEP 2009-336 - Rev 00
Issue Date : 2015-07-10
Type : Chemical
Substance Number : 1739
Status : Valid
NDC Package Code : 63190-0420
Start Marketing Date : 2011-07-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Alvogen Korea Co., Ltd.
Registration Date : 2021-11-10
Registration Number : 20110331-140-H-75-02(4)
Manufacturer Name : Industriale Chimica Srl
Manufacturer Address : Via EH Grieg, 13, 21047 SARONNO (VARESE), Italy
Certificate Number : R1-CEP 2011-124 - Rev 00
Issue Date : 2017-07-13
Type : Chemical
Substance Number : 1739
Status : Withdrawn by Holder
Certificate Number : R1-CEP 2010-294 - Rev 00
Issue Date : 2016-12-14
Type : Chemical
Substance Number : 1739
Status : Valid
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2020-08-13
Registration Number : 20200813-140-H-373-04
Manufacturer Name : Symbiotica Specialty Ingredients Sdn. Bhd.
Manufacturer Address : No. 518, Jalan Waja 4, Taman Industri Waja, 09000 Kulim, Kedah, Malaysia
Certificate Number : R1-CEP 2012-329 - Rev 02
Issue Date : 2023-07-20
Type : Chemical
Substance Number : 1739
Status : Valid
NDC Package Code : 24002-0033
Start Marketing Date : 2009-09-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sungjin Exim Co., Ltd.
Registration Date : 2021-07-15
Registration Number : 20210715-140-H-391-05
Manufacturer Name : Newchem SPA
Manufacturer Address : Via Roveggia, 47-37136 VERONA (VR), Italy
Date of Issue : 2020-09-08
Valid Till : 2023-04-24
Written Confirmation Number : WC-0402A2
Address of the Firm : Plot no. 23-24 GIDC Estate Nandesari-391340 Dist Vadodara Gujarat
Registrant Name : Synex Co., Ltd.
Registration Date : 2010-08-31
Registration Number : 20100831-140-H-28-01
Manufacturer Name : Aspen Oss BV
Manufacturer Address : Veersemeer 4, Oss, 5347 JN, The Netherlands
Registrant Name : Darim Biotech Co., Ltd.
Registration Date : 2016-12-07
Registration Number : 20110331-140-H-75-02(1)
Manufacturer Name : INDUSTRIAL CHIMICA SRL
Manufacturer Address : VIA EH Grieg 13 20147 SARONNO (VARESE), ITALY
Registrant Name : Alvogen Korea Co., Ltd.
Registration Date : 2021-11-10
Registration Number : 20110331-140-H-75-02(4)
Manufacturer Name : Industriale Chimica Srl
Manufacturer Address : Via EH Grieg, 13, 21047 SARONNO (VARESE), Italy
Registrant Name : Myungmoon Pharmaceutical Co., Ltd.
Registration Date : 2020-09-08
Registration Number : 20110331-140-H-75-02(3)
Manufacturer Name : INDUSTRIAL CHIMICA SRL
Manufacturer Address : VIA EH Grieg 13 21047 SARONNO (VARESE), ITALY
Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2011-03-31
Registration Number : 20110331-140-H-75-02
Manufacturer Name : INDUSTRIAL CHIMICA SRL
Manufacturer Address : VIA EH Grieg 13 21047 SARONNO (VARESE), ITALY
Registrant Name : GL Pharma Co., Ltd.
Registration Date : 2019-10-30
Registration Number : 20110331-140-H-75-02(2)
Manufacturer Name : Industriale Chimica srl
Manufacturer Address : via EHGrieg 13 21047 - Saronno (Varese), Italy
Registrant Name : Sungjin Exim Co., Ltd.
Registration Date : 2021-07-15
Registration Number : 20210715-140-H-391-05
Manufacturer Name : Newchem SPA
Manufacturer Address : Via Roveggia, 47-37136 VERONA (VR), Italy
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2014-03-07
Registration Number : 20140306-140-H-248-03
Manufacturer Name : Qinhuangdao Zizhu Pharmaceut...
Manufacturer Address : No.10, Longhai Road, Economic & Technological Development Zone, Qinhuangdao, Hebei, P...
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2020-08-13
Registration Number : 20200813-140-H-373-04
Manufacturer Name : Symbiotica Specialty Ingredi...
Manufacturer Address : No. 518, Jalan Waja 4, Taman Industri Waja, 09000 Kulim, Kedah, Malaysia
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Italy
Brand Name : MENEC
Dosage Form : Tablets
Dosage Strength : 2.5 mg
Packaging : 30 UNITS 2.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : SHYLA
Dosage Form : Tablets
Dosage Strength : 2.5 mg
Packaging : 30 UNITS 2.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tibolon-Mepha
Dosage Form : Tabl
Dosage Strength : 2.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Livial
Dosage Form : HARD CAPSULES
Dosage Strength : 1.25 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Livial
Dosage Form : Tibolone 2,5Mg 30 Joined' Oral Use
Dosage Strength : 30 CPR 2.5 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Livial
Dosage Form : Tabl
Dosage Strength : 2.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Livial
Dosage Form : TABLET
Dosage Strength : 2.5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Livial
Dosage Form : Antic-calc Tablet
Dosage Strength : 2.5 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Livial
Dosage Form : Tablet
Dosage Strength : 2.5 mg
Packaging : Blisterpakning 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tibolon Sandoz
Dosage Form : Tabl
Dosage Strength : 2.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Tibolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tibolone, including repackagers and relabelers. The FDA regulates Tibolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tibolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tibolone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tibolone supplier is an individual or a company that provides Tibolone active pharmaceutical ingredient (API) or Tibolone finished formulations upon request. The Tibolone suppliers may include Tibolone API manufacturers, exporters, distributors and traders.
click here to find a list of Tibolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tibolone DMF (Drug Master File) is a document detailing the whole manufacturing process of Tibolone active pharmaceutical ingredient (API) in detail. Different forms of Tibolone DMFs exist exist since differing nations have different regulations, such as Tibolone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tibolone DMF submitted to regulatory agencies in the US is known as a USDMF. Tibolone USDMF includes data on Tibolone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tibolone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tibolone suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tibolone Drug Master File in Korea (Tibolone KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tibolone. The MFDS reviews the Tibolone KDMF as part of the drug registration process and uses the information provided in the Tibolone KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tibolone KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tibolone API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tibolone suppliers with KDMF on PharmaCompass.
A Tibolone CEP of the European Pharmacopoeia monograph is often referred to as a Tibolone Certificate of Suitability (COS). The purpose of a Tibolone CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tibolone EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tibolone to their clients by showing that a Tibolone CEP has been issued for it. The manufacturer submits a Tibolone CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tibolone CEP holder for the record. Additionally, the data presented in the Tibolone CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tibolone DMF.
A Tibolone CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tibolone CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tibolone suppliers with CEP (COS) on PharmaCompass.
A Tibolone written confirmation (Tibolone WC) is an official document issued by a regulatory agency to a Tibolone manufacturer, verifying that the manufacturing facility of a Tibolone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tibolone APIs or Tibolone finished pharmaceutical products to another nation, regulatory agencies frequently require a Tibolone WC (written confirmation) as part of the regulatory process.
click here to find a list of Tibolone suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tibolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tibolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tibolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tibolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tibolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tibolone suppliers with NDC on PharmaCompass.
Tibolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tibolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tibolone GMP manufacturer or Tibolone GMP API supplier for your needs.
A Tibolone CoA (Certificate of Analysis) is a formal document that attests to Tibolone's compliance with Tibolone specifications and serves as a tool for batch-level quality control.
Tibolone CoA mostly includes findings from lab analyses of a specific batch. For each Tibolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tibolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Tibolone EP), Tibolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tibolone USP).
LOOKING FOR A SUPPLIER?